IS5502A - Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli - Google Patents

Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli

Info

Publication number
IS5502A
IS5502A IS5502A IS5502A IS5502A IS 5502 A IS5502 A IS 5502A IS 5502 A IS5502 A IS 5502A IS 5502 A IS5502 A IS 5502A IS 5502 A IS5502 A IS 5502A
Authority
IS
Iceland
Prior art keywords
treatment
prostate cancer
compounds useful
conjugated compounds
conjugated
Prior art date
Application number
IS5502A
Other languages
English (en)
Inventor
F. Brady Stephen
Feng Dong-Mei
M. Garsky Victor
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of IS5502A publication Critical patent/IS5502A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
IS5502A 1997-12-02 2000-05-19 Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli IS5502A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer
PCT/US1998/025358 WO1999028345A1 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
IS5502A true IS5502A (is) 2000-05-19

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5502A IS5502A (is) 1997-12-02 2000-05-19 Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli

Country Status (26)

Country Link
US (2) US20060148718A1 (is)
EP (1) EP1036093A1 (is)
JP (1) JP2001525337A (is)
KR (1) KR100580137B1 (is)
CN (1) CN1181092C (is)
AR (1) AR016427A1 (is)
AU (1) AU744652B2 (is)
BG (1) BG65486B1 (is)
BR (1) BR9815116A (is)
CA (1) CA2311615A1 (is)
DZ (1) DZ2665A1 (is)
EA (1) EA002745B1 (is)
EE (1) EE200000333A (is)
HR (1) HRP20000367A2 (is)
HU (1) HUP0100350A3 (is)
ID (1) ID24735A (is)
IL (1) IL136167A0 (is)
IS (1) IS5502A (is)
NO (1) NO20002804L (is)
NZ (1) NZ504615A (is)
PE (1) PE20000009A1 (is)
PL (1) PL197006B1 (is)
SK (1) SK8282000A3 (is)
TR (1) TR200002260T2 (is)
TW (1) TW577897B (is)
WO (1) WO1999028345A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518000A (ja) * 1998-12-11 2003-06-03 コールター ファーマシューティカル，インコーポレイティド プロドラッグ化合物およびその調製方法
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2014028057A1 (en) * 2012-08-15 2014-02-20 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
CN104884056A (zh) * 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US11474706B2 (en) 2013-04-30 2022-10-18 Hewlett Packard Enterprise Development Lp Memory access rate
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
GR81790B (is) * 1983-04-29 1984-12-12 Omnichem Sa
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
EP0855910A4 (en) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugates that can be used to treat benign prostate hyperplasia
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU715632B2 (en) * 1996-09-12 2000-02-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
JP2001525337A (ja) 2001-12-11
AR016427A1 (es) 2001-07-04
TR200002260T2 (tr) 2000-12-21
HRP20000367A2 (en) 2000-12-31
CN1181092C (zh) 2004-12-22
WO1999028345A1 (en) 1999-06-10
HUP0100350A3 (en) 2001-09-28
KR100580137B1 (ko) 2006-05-16
HUP0100350A2 (hu) 2001-08-28
SK8282000A3 (en) 2000-11-07
AU744652B2 (en) 2002-02-28
BR9815116A (pt) 2000-10-10
KR20010032687A (ko) 2001-04-25
CN1284086A (zh) 2001-02-14
ID24735A (id) 2000-08-03
BG104563A (en) 2001-04-30
DZ2665A1 (fr) 2003-03-22
TW577897B (en) 2004-03-01
EE200000333A (et) 2001-08-15
IL136167A0 (en) 2001-05-20
PE20000009A1 (es) 2000-01-27
NO20002804L (no) 2000-07-21
NO20002804D0 (no) 2000-05-31
US20070021350A1 (en) 2007-01-25
PL197006B1 (pl) 2008-02-29
AU1612399A (en) 1999-06-16
BG65486B1 (bg) 2008-09-30
EP1036093A1 (en) 2000-09-20
PL340768A1 (en) 2001-02-26
EA002745B1 (ru) 2002-08-29
NZ504615A (en) 2003-05-30
US20060148718A1 (en) 2006-07-06
CA2311615A1 (en) 1999-06-10
EA200000603A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
IS5025A (is) Samtengd efnasambönd nytsamleg við meðhöndlunina á krabbameini í blöðruhálskirtli
IS6375A (is) Lyfjagjöf til öftrunar á blöðruhálskrabbameini
ID24118A (id) Terapi gabungan
NO994069D0 (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmåte for anvendelse derav
ID27841A (id) Turunan-turunan biaril terapeutik
ID24275A (id) Terapi kombinasi
FI20031516A7 (fi) Indolokarbatsolijohdannaisten käyttö eturauhasen patologisten tilojen hoidossa
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
AUPQ923100A0 (en) Treatment of prostate cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
DE69911967D1 (de) Schleifkörper
IT1306822B1 (it) Calzoncino per il trattamento topico della cellulite.
GB9827102D0 (en) New cancer treatments
GB9718160D0 (en) Conjugates useful in the treatment of prostate cancer
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
GB9810183D0 (en) Conjugates useful in the treatment of prostate cancer
GB9815855D0 (en) Conjugates useful in the treatment of prostate cancer
GB9804399D0 (en) Conjugates useful in the treatment of prostate cancer
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
GB9626309D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
GB9903035D0 (en) Treating cancer